Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of the Combination of Ibrutinib and Lenalidomide for the Treatment of Patients With MDS Who Have Failed or Refuse Standard Therapy

NCT03359460 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT03359460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03359460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of the Combination of Ibrutinib and Lenalidomide for the Treatment of Patients With MDS Who Have Failed or Refuse Standard Therapy
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2017
Completion date
November 17, 2019
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome, previously treated myelodysplastic syndrome, refractory high risk myelodysplastic syndrome, secondary myelodysplastic syndrome, therapy-related myelodysplastic syndrome